Supplemental Figure 4 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Year: 2023
Type: supplementary-materials
Abstract: GNE-900 can potentiate the cytotoxicity of gemcitabine, SN-38 and pemetrexed.
Authors: Elizabeth Blackwood, Jennifer Epler, Ivana Yen, Michael Flagella, Tom O'Brien, Marie Evangelista, Stephen Schmidt, Yang Xiao, Jonathan Choi, Kaska Kowanetz, Judi Ramiscal, Kenton Wong, Diana Jakubiak, Sharon Yee, Gary Cain, Lewis Gazzard, Karen Williams, Jason Halladay, Peter K. Jackson, Shiva Malek
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362477902